Surveillance of antimicrobial resistance at a tertiary hospital in Tanzania by Blomberg, Bjørn et al.
BioMed Central
Page 1 of 11
(page number not for citation purposes)
BMC Public Health
Open AccessResearch article
Surveillance of antimicrobial resistance at a tertiary hospital in 
Tanzania
Bjørn Blomberg*1,2,3, Davis SM Mwakagile3, Willy K Urassa3, 
Samwel Y Maselle3, Marcellina Mashurano3, Asbjørn Digranes4, 
Stig Harthug2 and Nina Langeland1,2,5
Address: 1Centre for International Health, University of Bergen, N-5021 Bergen, Norway, 2Institute of Medicine, University of Bergen, N-5021 
Bergen, Norway, 3Department of Microbiology and Immunology, Muhimbili University College of Health Sciences, Dar es Salaam, Tanzania, 
4Department of Microbiology and Immunology, the Gade Institute, Haukeland Hospital, N-5021 Bergen, Norway and 5Department of Medicine, 
Haukeland University Hospital, N-5021 Bergen, Norway
Email: Bjørn Blomberg* - bjorn.blomberg@cih.uib.no; Davis SM Mwakagile - dmwakagile@muchs.ac.tz; Willy K Urassa - wurassa@muchs.ac.tz; 
Samwel Y Maselle - smaselle@muchs.ac.tz; Marcellina Mashurano - mashurano@yahoo.com; Asbjørn Digranes - nina.langeland@helse-
bergen.no; Stig Harthug - stig.harthug@helse-bergen.no; Nina Langeland - nina.langeland@helse-bergen.no
* Corresponding author    
Abstract
Background: Antimicrobial resistance is particularly harmful to infectious disease management in
low-income countries since expensive second-line drugs are not readily available. The objective of
this study was to implement and evaluate a computerized system for surveillance of antimicrobial
resistance at a tertiary hospital in Tanzania.
Methods: A computerized surveillance system for antimicrobial susceptibility (WHONET) was
implemented at the national referral hospital in Tanzania in 1998. The antimicrobial susceptibilities
of all clinical bacterial isolates received during an 18 months' period were recorded and analyzed.
Results: The surveillance system was successfully implemented at the hospital. This activity
increased the focus on antimicrobial resistance issues and on laboratory quality assurance issues.
The study identified specific nosocomial problems in the hospital and led to the initiation of other
prospective studies on prevalence and antimicrobial susceptibility of bacterial infections.
Furthermore, the study provided useful data on antimicrobial patterns in bacterial isolates from the
hospital. Gram-negative bacteria displayed high rates of resistance to common inexpensive
antibiotics such as ampicillin, tetracycline and trimethoprim-sulfamethoxazole, leaving
fluoroquinolones as the only reliable oral drugs against common Gram-negative bacilli. Gentamicin
and third generation cephalosporins remain useful for parenteral therapy.
Conclusion: The surveillance system is a low-cost tool to generate valuable information on
antimicrobial resistance, which can be used to prepare locally applicable recommendations on
antimicrobial use. The system pinpoints relevant nosocomial problems and can be used to
efficiently plan further research. The surveillance system also functions as a quality assurance tool,
bringing attention to methodological issues in identification and susceptibility testing.
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Background
Exaggerated and irrational use of drugs, availability of
antibiotics without prescription, the use of pharmaceuti-
cals of doubtful quality and the HIV epidemic may all
contribute to the current worldwide surge in antimicro-
bial drug resistance. Emerging resistance to antimicrobial
drugs increases morbidity and mortality by hampering the
provision of effective chemotherapy, and makes treat-
ment more costly [1-3]. The surge in antimicrobial resist-
ance seen in many low-income countries is potentially
disastrous because of the lack of resources for purchasing
expensive second-line drugs [4].
It is widely held that surveillance of antimicrobial suscep-
tibility is fundamental to combat the emergence of resist-
ance [5]. Surveillance must be global since resistant
bacteria can be transferred between countries, but it must
also be local, since countries have very different resistance
patterns and different treatment practices [6]. The primary
task of a surveillance system is to provide locally applica-
ble data to guide empiric therapy. Furthermore, surveil-
lance may help assessing the magnitude of the resistance
problem locally, nationally and internationally, monitor-
ing changes in resistance rates and detecting the emer-
gence and spread of new resistance traits. A well-
functioning surveillance system is also necessary to meas-
ure the impact of any interventions. Surveillance systems
also functions as a quality assurance tool and may help
improving the quality of the susceptibility testing.
This paper describes the experience with the implementa-
tion of a computerized surveillance system for antimicro-
bial drug susceptibility at Tanzania's major referral
hospital, and its use to analyze the susceptibility patterns
of 7621 consecutively recorded clinical bacterial isolates.
Methods
Setting
The study was performed at Muhimbili National Hospital
(MNH), Dar es Salaam, Tanzania. With more than 1000
beds, MNH is the largest hospital in the country and
serves as a national referral and university teaching hospi-
tal, as well as a primary and referral hospital for a popula-
tion of approximately 3.6 million in the Dar es Salaam
area. The Department of Microbiology and Immunology
at MNH examines specimens from inpatients and outpa-
tients at MNH, and from a number of nearby hospitals.
Bacteriological cultures are performed on more than
23,000 specimens per year.
The surveillance system
A free-of-charge software for the surveillance of antimicro-
bial resistance (WHONET, World Health Organization,
Geneva, Switzerland) [7] was implemented at MNH in
1998. Currently a total of 880 microbiology laboratories
in 76 countries use this software, however, among these
are only 41 laboratories in four countries on the African
continent (data from 2002, personal communication
from John Stelling, author of the WHONET software). The
software has three main parts, a laboratory configuration
file which can be used to customize it to the particular lab-
oratory, an interface for data entry and a part for analysis
and reporting of resistance data. At our hospital, all bacte-
rial isolates of clinical significance from specimens
received during the period July 1st 1998 to December 31st
1999 were recorded and analyzed. The specimens exam-
ined included urine, pus/secretions (swabs from skin, sur-
gical and traumatic wounds, burns, umbilical cords,
throat, nose, eye and ear discharge and genital swabs),
blood, cerebrospinal fluid, other body fluids, stools and
other specimens. Mycobacteria and anaerobic bacteria
were not included in the study. Apart from the WHONET
software, we used Stata 8.0 for Macintosh (Stata Corpora-
tion, College Station, Texas, USA) to evaluate differences
of proportions by Fisher's exact test (2-tailed, cut-off point
for statistical significance at p-value of 0.05).
Laboratory methods
The specimens were cultured and the bacterial isolates
identified using standard microbiological methods as
described in Mackie & McCartney Practical Medical Micro-
biology [8]. Susceptibility testing was performed by
Stokes' method [9] on Iso-Sensitest (Oxoid Limited, Bas-
ingstoke, UK) agar plates. This method, developed by Dr
Joan Stokes half a century ago, was designed to monitor
for both disc and agar quality in that both the clinical iso-
late and a control strain were tested on every plate. The
clinical isolate is swabbed onto the middle of the agar
plate and the control strain at the periphery. The antibi-
otic disk is placed precisely at the interface between the
surface areas inoculated with the clinical isolate and the
control strain. After overnight incubation, the relative size
of the inhibition zones of the clinical isolate and the con-
trol strains are compared. The test results are classified as
susceptible (S), intermediate (I) or resistant (R) by evalu-
ation of the difference between the inhibition zones of the
clinical isolate and the control strain. The control strains
used in our lab are S. aureus NCTC 6571, E. coli NCTC
10418 or Pseudomonas aeruginosa NCTC 10662. The iso-
lates showing intermediate resistance were few and were
grouped together with sensitive isolates for the purpose of
data analysis. Either methicillin or oxacillin disks were
used to test for methicillin-resistance in S. aureus, the
results being considered equivalent and interchangeable
in the data analysis. ß-Lactamase testing was not routinely
performed. The susceptibility of pneumococci to penicil-
lin was examined by the use of penicillin 2 µg disks. Com-
mercially produced antibiotic disks, mostly obtained
from Oxoid Limited, were used, however, in some
instances, antibiotic disks, prepared locally were used due
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to financial constraints. The Department of Microbiology
and Immunology participates in an external quality
assessment program in bacteriology led by the World
Health Organization-collaborating centre, the National
Institute for Communicable Diseases (NICD), Johannes-
burg, South Africa. The Department of Microbiology and
Immunology at our hospital receives bacterial strains
from NICD, performs species identification and antimi-
crobial susceptibility testing, and report the results back to
NICD.
Evaluation of the surveillance system
We evaluated the strengths and shortcomings of the sur-
veillance system in our setting, particularly in terms of
how well it performed in its main application areas, pro-
viding locally applicable data to guide empiric therapy,
monitoring antimicrobial susceptibility trends, detecting
the emergence and spread of new resistance traits and as a
tool for quality assurance. We also assessed the cost-impli-
cations of implementing the surveillance program in our
setting. We considered direct costs, such as the purchase of
equipment, and indirect costs, such as those related to the
running of the laboratory, including human resources. We
also comment on the benefits of the surveillance system
related to both direct patient care and long-term implica-
tions of containing antimicrobial resistance.
Results
Bacterial isolates
A total of 7617 bacterial isolates were registered during
the study period, of which 67.4% (n = 5134) were Gram-
negative and 32.6% (n = 2483) Gram-positive. Table 1
shows the most frequently encountered bacteria, overall
and from various specimen types. The majority of the iso-
lates were obtained from pus (44.3%), urine (43.5%) and
blood cultures (10.1%). Cerebrospinal fluid accounted
for 0.4% of the isolates. Among the 2034 blood cultures,
15.9% (n = 323) yielded growth of a total of 326 patho-
genic bacterial isolates and 447 Coagulase-negative
staphylococci (CoNS) as shown in Table 1. CoNS are
potential pathogens and are increasingly considered as a
cause of blood-stream infections. However, in many cases
they are merely contaminants, i.e. bacterial isolates
present on the skin surface, which are introduced in the
blood specimen and grow in the blood culture, but do not
produce disease in the patient. For CoNS isolates to be
considered a probable pathogen, it is commonly required
that they are recovered from two separate blood cultures.
Since multiple blood cultures were not routinely taken
from the same patient in the hospital, the susceptibilities
of these isolates were not evaluated further. CoNS and var-
ious other Gram-positive probable contaminants, mostly
Bacillus spp. were recovered from 22.0% (n = 447) and
6.9% (n = 141) of the blood cultures, respectively. Fur-
thermore, five Candida spp. isolates and one Cryptococcus
Table 1: Frequency of pathogenica bacterial isolates from different specimen types at Muhimbili National Hospital, Tanzania
Organism Blood (%) Spinal fluid (%) Urine (%) Pusb(%) Other (%) Overall (%)
Gram-negative isolates
E. coli 27 (3.5) 0 (0.0) 1466 (44.2) 417 (12.3) 26 (21.8) 1936 (25.4)
Klebsiella spp. 91 (11.8) 8 (23.5) 1036 (31.3) 603 (17.9) 33 (27.7) 1771 (23.3)
Pseudomonas spp. 10 (1.3) 2 (5.9) 52 (1.6) 531 (15.7) 9 (7.6) 604 (7.9)
Proteus spp. 7 (0.9) 0 (0.0) 121 (3.7) 249 (7.4) 3 (2.5) 380 (5.0)
Enterobacter spp. 4 (0.5) 0 (0.0) 97 (2.9) 1 (0.0) 0 (0.0) 102 (1.3)
Salmonella spp. 37 (4.8) 2 (5.9) 6 (0.2) 0 (0.0) 4 (3.4) 49 (0.6)
N. gonorrhoeae 0 (0.0) 0 (0.0) 0 (0.0) 41 (1.2) 0 (0.0) 41 (0.5)
Haemophilus spp. 1 (0.1) 5 (14.7) 0 (0.0) 0 (0.0) 0 (0.0) 6 (0.1)
Other GNR 32 (4.1) 7 (20.6) 12 (0.4) 184 (5.4) 10 (8.4) 245 (3.2)
Subtotal, Gram-negative isolates 209 (27.0) 24 (70.6) 2790 (84.2) 2026 (60.0) 85 (71.4) 5134 (67.4)
Gram-positive isolates
Staphylococcus aureus 72 (9.3) 1 (2.9) 362 (10.9) 1120 (33.2) 12 (10.1) 1567 (20.6)
Streptococcus pyogenes 1 (0.1) 0 (0.0) 0 (0.0) 160 (4.7) 2 (1.7) 163 (2.1)
Other streptococcic 39 (5.0) 3 (8.8) 52 (1.6) 58 (1.7) 13 (10.9) 165 (2.2)
Enterococci 3 (0.4) 0 (0.0) 64 (1.9) 3 (0.1) 1 (0.8) 71 (0.9)
S. pneumoniae 2 (0.3) 6 (17.6) 0 (0.0) 11 (0.3) 6 (5.0) 25 (0.3)
CoNSa 447 (57.8) ... 45 (1.4) ... ... 492 (6.5)
Subtotal, Gram-positive isolates 564 (73.0) 10 (29.4) 523 (15.8) 1352 (40.0) 34 (28.6) 2483 (32.6)
Total 773 (100.0) 34 (100.0) 3313 (100.0) 3378 (100.0) 119 (100.0) 7617 (100.0)
GNR, Gram-negative rod-shaped bacteria, not further identified; CoNS, coagulase-negative staphylococci; "...", not applicable.a CoNS from blood 
and urine specimens are reported as possible pathogens, although many may be contaminants. CoNS from other specimen types are considered 
contaminants and not reported. b Pus includes swabs from skin, surgical and traumatic wounds, burns, umbilical cords, throat, nose, eye and ear 
discharge and genital swabs. c Streptococci other than S. pyogenes and S. pneumoniae, and streptococci not identified below genus level.
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neoformans were recovered. Among the 49 Salmonella iso-
lates, two were identified as S. Typhi, 16 as S. Typhimu-
rium, 16 as S. Paratyphi B and one each as S. Paratyphi C,
S. Enteritidis and S. Arizonae. Twelve Salmonella isolates
were not serotyped. Among the 41gonococcal isolates, 28
(68.3%) were from genital swabs. Eleven (26.8%) gono-
coccal isolates were obtained from the neonatal ward, out
of which 4 were specified as from eye discharge.
Specimens from inpatients and outpatients contributed to
53.2% and 31.9% of the isolates, respectively. A further
6.0% were obtained from specimens from other hospitals
in Dar es Salaam, while 8.8% were obtained from other or
unknown locations. Among the isolates from inpatients,
36.5% were obtained from the Department of Pediatrics,
28.4% from the neonatal section and 8.1% from the other
pediatric wards. The other isolates came from the Depart-
ments of Surgery (22.4%), Internal Medicine (16.6%),
Obstetrics and Gynecology (9.8%), the Intensive Care
Unit (4.9%) and other locations (9,8%). For 4900 iso-
lates, the age or the estimated age group of the patient was
known. Of these, 23.6% (n = 1155) were from neonates
(≤ 1 month old), 6.8% (n = 335) from children aged one
month to seven years, and 69.6% (n = 3410) from adults
or children older than 8 years.
Antimicrobial susceptibility
Tables 2 and Table 3 show the antimicrobial susceptibility
patterns of the most frequently isolated Gram-negative
and Gram-positive bacteria, respectively. There were no
clear-cut differences in the antimicrobial susceptibilities
among the various serotypes of Salmonella isolates (data
not shown). The majority of Pseudomonas aeruginosa iso-
lates was susceptibility-tested to gentamicin only, to
which 4.3% (15/350) were resistant. Among the isolates
of Neisseria gonorrhoeae, 70.0% were resistant to penicillin,
45.2% to tetracycline, 59.3% to trimethoprim-sulfameth-
oxazole, 5.9% to erythromycin and none was resistant to
spectinomycin, fluoroquinolones or amoxicillin-clavu-
lanate (data not shown).
Table 2: Percentage of Gram-negative bacterial isolates resistant to antimicrobial agents (number of tested isolates in brackets)
Drug E. coli Klebsiella spp. Proteus spp. Enterobacter spp. Salmonella spp. GNR
Ampicillin 80% (1761) 85% (1572) 60% (331) 72% (86) 70% (46) 56% (204)
Amoxicillin- 
clavulanate
28% (1292) 32% (1153) 17% (247) 32% (78) 52% (23) 31% (124)
Ceftazidime 5% (788) 6% (605) 2% (95) 10% (51) 0% (8) 14% (35)
Tetracycline 77% (1223) 66% (1016) 77% (211) 72% (54) 42% (12) 45% (153)
Gentamicin 8% (1634) 14% (1538) 7% (343) 15% (91) 9% (23) 8% (217)
Trimethoprim- 
sulfamethoxazole
76% (1313) 69% (1174) 57% (224) 70% (56) 73% (44) 51% (172)
Sulfonamides 84% (174) 84% (231) 74% (46) 100% (14) 95% (22) 62% (34)
Nitrofurantoin 32% (929) 53% (652) 72% (71) 48% (48) ... ...
Chloramphenicol 45% (250) 51% (372) 55% (132) ... 20% (41) 57% (138)
Fluoroquinolones 13% (432) 6% (343) 3% (65) 6% (32) 0% (20) 15% (40)
Nalidixic acid 28% (509) 16% (334) 18% (22) 31% (16) ... ...
GNR, Gram negative rod-shaped bacteria, not further identified; "...", not tested.
Table 3: Percentage of Gram-positive bacterial isolates resistant to antimicrobial agents (number of tested isolates in brackets)
Drug S. aureus CoNS Enterococci S. pneumoniae S. pyogenes Other strept.a
Penicillin 97% (1521) 93% (42) 67% (9) 4% (23) 0% (163) 23% (98)
Ampicillin ... ... 6% (66) ... ... 13% (83)
Methicillin/ cloxacillin 2% (1556) 21% (47) ... ... ... ...
Tetracycline 49% (1042) 90% (39) 76% (51) 8% (13) 47% (131) 61% (90)
Erythromycin 29% (1543) 69% (48) 26% (65) 6% (18) 7% (161) 26% (156)
CoNS, Coagulase-negative staphylococci; "...", not tested. a Streptococci other than S. pyogenes and S. pneumoniae, and streptococci not identified 
below genus level.
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Comparison of resistance patterns of isolates obtained
from inpatients and outpatients at MNH did not show
large differences. However, ampicillin resistance was
more frequent in urinary isolates of E. coli from inpatients
than in those from outpatients as shown in Table 4. Like-
wise, urinary isolates of Klebsiella spp. from inpatients
were more frequently resistant to gentamicin and trimeth-
oprim-sulfamethoxazole than isolates from outpatients.
Comparison of resistance patterns in isolates blood cul-
tures with those from other specimen types showed
apparent great differences for some drugs, however, in
most cases the number of blood culture isolates were few
and did not show statistically significant differences.
However, as shown in Table 5, blood culture isolates of
Klebsiella spp. were indeed more frequently resistant to
gentamicin than those from other specimen types. A sig-
nificantly greater proportion of blood culture isolates of S.
aureus were resistant to tetracycline than among those
from other specimen types, whereas for penicillin the iso-
lates from blood cultures were resistant in a lower propor-
tion than the others.
Evaluation of the surveillance system
A great number of bacterial isolates were recorded in the
system. All age groups and both inpatients and outpa-
tients were represented in the study. More than a third of
the isolates were from outpatient populations from the
Table 4: Percentage of urinary E. coli and Klebsiella spp. isolates from inpatients and outpatients resistant to antimicrobial agents
E. coli Klebsiella spp.
Drug Inpatients Outpatients Pa Inpatients Outpatients Pa
Ampicillin 87.2 82.7 0.036a 92.2 91.1 0.624
Amoxicillin- clavulanate 31.4 28.3 0.344 37.7 33.9 0.327
Ceftazidime 4.9 5.6 0.731 7.6 6.0 0.577
Tetracycline 83.1 81.7 0.648 82.0 75.2 0.053
Gentamicin 8.6 7.7 0.572 14.9 5.4 <0.001a
Trimethoprim- sulfamethoxazole 86.0 81.3 0.067 82.7 74.2 0.012a
Sulfonamides 92.1 87.8 0.510 95.2 100.0 0.553
Nitrofurantoin 33.7 33.1 0.881 52.1 58.0 0.157
Fluoroquinolones 17.8 12.7 0.217 7.2 6.7 1.000
Nalidixic acid 29.0 28.2 0.913 14.0 18.8 0.334
a P < 0.05 (Fisher's exact test, 2-tailed) indicates statistical significance of the differences in resistance rates.
Table 5: Percentage of bacterial isolates from different specimen types resistant to antimicrobial agents
E. coli Klebsiella spp. S. aureus
Drug Blood Other Pa Blood Other Pa Blood Other Pa
Penicillin ... ... ... ... ... ... 91.5 96.9 0.028a
Ampicillin 84.0 79.4 0.803 84.3 85.3 0.759 ... ... ...
Amoxicillin- clavulanate 40.0 27.8 0.383 29.8 31.9 0.873 ... ... ...
Methicillin ... ... ... ... ... ... 1.4 2.2 1.000
Ceftazidime 0.0 5.3 1.000 5.7 6.0 1.000 ... ... ...
Tetracycline 54.5 77.3 0.139 66.7 66.4 1.000 84.6 48.3 <0.001a
Erythromycin ... ... ... ... ... ... 21.1 29.0 0.179
Gentamicin 13.0 7.7 0.416 41.3 12.3 <0.001a ... ... ...
Trimethoprim- sulfamethoxazole 72.0 76.3 0.636 63.0 69.1 0.297 ... ... ...
Sulfonamides 83.3 84.0 1.000 86.8 83.4 0.809 ... ... ...
Chloramphenicol 58.3 43.8 0.199 57.9 49.3 0.200 ... ... ...
Fluoroquinolones 40.0 13.1 0.136 0.0 6.5 0.381 ... ... ...
"...", not applicable. a P < 0.05 (Fisher's exact test, 2-tailed) indicates statistical significance of the differences in resistance rates.
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Dar es Salaam area, however we cannot exclude the possi-
bility of a selection bias in favour of patients with infec-
tions caused by resistant organisms, since many patients
get treatment at primary health facilities before reaching
MNH. We do not know how well the rural population is
represented in this material, but we assume that the out-
patients in the study are mostly from the Dar es Salaam
area. Ten percent of the isolates represented systemic
infections, i.e. isolates from blood cultures and spinal
fluid. The susceptibility test results were recorded as inter-
preted values (i.e. "R" (resistance), "I" (Intermediate) or
"S" (susceptible)) and not as inhibition zone diameters.
In this study, no molecular techniques were available for
the detection of resistance genotypes and evaluation of
genetic relatedness of bacterial isolates.
The direct cost of implementing the surveillance system
was limited to the purchase of a computer at approxi-
mately 1000 Euro. However, less expensive second-hand
computers would be sufficient. The software was down-
loaded free of charge from the WHO website. The indirect
costs of running this surveillance program are related to
human sources for operating the software, including data
entry and analysis, and the costs of the susceptibility test-
ing activities. It is difficult to separate these indirect costs
from the costs of running the daily laboratory activities. In
our setting, a laboratory technologist from the depart-
ment took on the task of operating the software in addi-
tion to her regular duties. In our experience, for a hospital
of our size, it is recommendable to allocate approximately
50% of a laboratory technologist position to operating the
surveillance software. In our setting, this would translate
into a monthly cost of approximately 100 Euro for the
department. The surveillance system is dependent on sus-
ceptibility testing of acceptable quality. The susceptibility
testing incurs costs related to human resources and the
purchase of laboratory reagents including antimicrobial
disks and agar media. Implementing a surveillance system
may increase these costs by focusing on the importance of
quality reagents. However, since the susceptibility testing
activities are an integral activity of the department, which
would have been performed regardless of the surveillance
system, we choose not to attribute their costs to the sur-
veillance system in this context. The benefits of a surveil-
lance system are difficult to quantify, but are of potentially
great magnitude. Foremost, surveillance data may
improve empiric therapy for infections and thus save lives
and reduce suffering. It may reduce treatment costs by
enabling the use of the least expensive effective drugs.
Additionally, surveillance systems may contribute to con-
taining or reducing antimicrobial resistance, which in the
long term perspective may have great benefits in reducing
morbidity and mortality, and diminish the need for
expensive second-line antimicrobial agents.
The strengths and weaknesses are elaborated on in the
Discussion part.
Discussion
Resistance patterns and implications for therapy
Experience from the World Health Organization's Exter-
nal quality assurance system for antimicrobial susceptibil-
ity testing has shown that disk diffusion testing is suitable
for routine surveillance [10]. However, disk diffusion is
not optimal for testing of certain important resistance
traits, such as penicillin-resistance in pneumococci. The
lack of international standardization of methods and
interpretive criteria causes concern, but there are indica-
tions that routine susceptibility testing data are suitable
for surveillance even if obtained with different methods
[11].
Consistent with observations from a number of other
countries in the region [12-15] and elsewhere [16], Gram-
negative bacilli displayed high rates of resistance to com-
mon inexpensive antibiotics. Reasonably priced antibiot-
ics such as ampicillin, tetracycline, trimethoprim-
sulfamethoxazole and sulfonamides are now of limited
benefit in the treatment of infections caused by important
Gram-negative bacteria such as E. coli, Klebsiella spp., Pro-
teus spp. and Salmonella. Chloramphenicol may fail to
cure as much as a quarter of infections caused by Salmo-
nella and half or more of infections caused by E. coli, Kleb-
siella spp. and Proteus spp. Fluoroquinolones appear to be
the only reliable drugs for oral treatment of infections
caused by common Gram-negative bacilli, whereas gen-
tamicin and third-generation cephalosporins remain use-
ful for parenteral therapy.
The study showed a very low prevalence of methicillin-
resistant S. aureus, consistent with previous data from the
same hospital [17,18]. While the results should be inter-
preted with some caution since confirmatory nucleic acid
based techniques were not available, the data support the
current use of isoxazolyl penicillins, such as cloxacillin for
the treatment of staphylococcal infections at the hospital.
There were few isolates of enterococci compared to studies
from high-income countries [19]. It is reassuring that the
current study showed a low rate of ampicillin-resistant
enterococci, indicating that nosocomial infections caused
by these micro-organisms is a minor problem compared
with many high-income countries. Low consumption of
broad-spectrum antibiotics such as third-generation
cephalosporins, fluoroquinolones, imipenem and vanco-
mycin may explain this finding [19-21]. While other
countries in the region have been affected by penicillin-
resistant pneumococci [22,23], the current study indicates
that pneumococcal disease in Dar es Salaam can safely be
treated with penicillin or erythromycin. However, the
results should be interpreted with some caution since the
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number of isolates tested was small. More than a quarter
of the gonococcal isolates (11/41) were obtained from the
neonatal ward, and most or all of these isolates probably
represent gonococcal conjunctivitis. Amoxicillin-clavu-
lanate, spectinomycin, fluoroquinolones and erythromy-
cin appear to be good alternatives for the treatment of
gonococcal infections. An apparent increase in resistance
to trimethoprim-sulfamethoxazole (from 18% to 59%) is
noted since the study by Mbwana [24] from 1993 to 1995,
however, this may be due to the use of different method-
ology for susceptibility testing.
Applicability of data to guide treatment of serious 
infections
Recommendations for antibiotic treatment of serious bac-
terial infections such as bloodstream infections and men-
ingitis should preferably be based on knowledge of the
prevalence and antimicrobial susceptibility patterns of
pathogens isolated from blood and spinal fluid. While a
fair number of bacterial isolates were tested in the current
study, the number of blood culture isolates was limited (n
= 329, excluding the CoNS isolates). As shown in Table 5,
there appears to be differences in resistance between iso-
lates obtained from blood cultures and those from other
specimen types, but these are difficult to assess because of
the low number of blood culture isolates. Thus, the data
from the current surveillance should be interpreted with
caution with regards to the treatment of serious infections.
The CoNS isolates obtained from blood were recorded in
the WHONET database, since they may represent clini-
cally important infections such as bacteremia in patients
with compromised immunity, patients with indwelling
intravascular devices and the newborn [25]. The study
showed that a high proportion (21.9%) of blood culture
bottles yielded CoNS isolates. However, the conventional
way to distinguish pathogenic isolates of CoNS from con-
taminants, by requiring growth of a similar CoNS isolate
in a separate blood culture, could rarely be used, since fol-
low-up cultures were seldom available. Consequently, the
susceptibilities of these isolates were not evaluated
further.
Relevance of data for outpatient and rural populations
It is important to specify for which population the surveil-
lance data are valid. At our hospital, specimens from both
inpatients and outpatients were examined. The hospital is
to a great extent used as a primary hospital for the popu-
lation in the Dar es Salaam area. However, among the
cases coming to the hospital, there may be a degree of
selection of patients with infections caused by resistant
microbes, since many patients rely on health centers and
pharmacies to cure simple ailments, and only come to the
hospital when primary treatment fails. The study found
that a few resistance traits, such as ampicillin resistance in
E. coli and gentamicin and trimethoprim-sulfamethoxa-
zole resistance in Klebsiella spp. were more frequent in uri-
nary isolates from inpatients than from outpatients. Apart
from that, there were no dramatic differences between
isolates from inpatients and outpatients. The data from
the study should be representative for both the hospital
setting and to some degree the population in Dar es
Salaam. However, the majority of the population of Tan-
zania lives in rural areas, where resistance patterns may be
substantially different. Thus one should be cautious to
extrapolate the results of the current study to be valid for
populations in the countryside.
Ability to monitor trends of antimicrobial susceptibility
Certain trends in antimicrobial susceptibility could be
identified by comparison with data from other studies.
While resistance to ampicillin, tetracycline and sulfona-
mides in Gram-negative bacteria was frequent already in
the seventies [26,27], it is worrying that resistance to tri-
methoprim-sulfamethoxazole, chloramphenicol, nitro-
furantoin, nalidixic acid and amoxicillin-clavulanate
appear to have increased compared to previous studies
[27,28]. The extensive use of chloramphenicol for the
treatment of presumed cases of typhoid fever and the use
of trimethoprim-sulfamethoxazole for the ambulatory
treatment of chest infections, malaria and other infec-
tions, may have contributed to the high prevalence of
resistance to these two drugs. Although still low, it is of
concern that the rate of gentamicin-resistance in E. coli has
increased from zero in 1978–79 [27] to 2% in 1995 [28]
and 8% in the current study. In neighboring Kenya, the
rate of gentamicin-resistance in E. coli has increased from
2% in the late seventies [29] to 20% and above in recent
studies [12].
Resistance to gentamicin is common in Gram-negative
bacteria with extended-spectrum beta-lactamases (ESBL),
sometimes in as much as 96% of isolates [30]. Such an
association cannot be investigated in the current study,
since less than half of the isolates of E. coli and Klebsiella
spp. were tested for susceptibility to third-generation
cephalosporins and other methods for detection of ESBL
(double disk synergy test, Etest, PCR) were not available.
Also in P. aeruginosa the rate of gentamicin-resistance has
increased, from zero in the seventies [27] to 4% in the cur-
rent study. Resistance to penicillin and erythromycin was
common among S. aureus isolates in this study. However,
the rate of tetracycline resistance (49%) was lower than
reported from the same hospital in 1979 (57%) and 1982
(74%) [17]. In the late seventies, tetracycline was used in
great quantities in Tanzania to prevent and treat cholera;
as much as 1788 kilograms of the drug were used during
a period of only 5 months [31]. Due to the rapid emer-
gence of tetracycline-resistant Vibrio cholerae, the use of the
drug was subsequently greatly reduced, and this may have
BMC Public Health 2004, 4:45 http://www.biomedcentral.com/1471-2458/4/45
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contributed to a concurrent decline in the rate of tetracy-
cline-resistance in an unrelated species such as S. aureus.
For meaningful comparison of data from different studies,
whether from the same or different laboratories, the same
method of susceptibility testing should preferably be
employed. In our laboratory, the same method has been
used for a number of years. The WHONET software fea-
tures a number of sophisticated ways to analyze suscepti-
bility information based on the measurements of
inhibition zone diameters. Recording the diameter of the
inhibition zones in disk diffusion testing is generally rec-
ommended [32], and may increase the accuracy of results
and enable the detection of gradual shifts in antibiotic
susceptibility over time. It also makes the data independ-
ent of the current breakpoints. With the WHONET soft-
ware, data can easily and rapidly be re-analyzed with
reference to new breakpoints. However, the Stokes'
method for susceptibility testing [9], which is used in our
laboratory, is based on visual interpretation of the differ-
ence in inhibition zones between the clinical isolate and
the control strain. The interpretation is recorded as inter-
preted values, i.e. either susceptible "S", intermediate sus-
ceptible "I" or resistant "R". The WHONET software also
accepts susceptibility data to be entered and analyzed as
"interpreted values", i.e. "S", "I" and "R". The use of such
interpreted values enables most of the analysis features of
WHONET, but not all. Foremost, analyzing data based on
zone diameters (or MIC values) is superior for the early
detection of subtle shifts in antimicrobial resistance over
time, which may alert clinicians about emerging resist-
ance trends at an early stage. However, one asset of the
Stokes' method, particularly under tropical conditions, is
that unsuspected poor antibiotic disk quality will be dis-
covered quickly since a control strain is tested on every
plate.
Furthermore, variations over time in the battery of antibi-
otics tested makes comparison of data less useful. Labora-
tories in low-income countries are sometimes vulnerable
to this because of unreliable supplies of antibiotic discs.
Ability to detect emerging resistance traits
Disk diffusion testing may give indications of emerging
resistance traits such as methicillin-resistance in S. aureus
and ESBL in Gram-negative bacteria. The current surveil-
lance indicated that methicillin-resistance is rare in S.
aureus at the hospital. Ideally this should be confirmed
with PCR-based methods to detect the mecA gene. Like-
wise, the disk diffusion testing showed the presence of
resistance to ceftazidime in Gram-negative isolates, albeit
at a low rate, which calls for further investigation with
regard to the possible presence of ESBL. Our laboratory
did not employ molecular methods for detection of resist-
ance genes on a routine basis, but a recent study showed
low prevalence of methicillin-resistant S. aureus (MRSA)
[18]. Resistance surveillance should be coupled with
awareness of signs of various resistance traits and,
preferably, the possibility of using molecular methods to
verify emerging resistance traits.
Ability to detect nosocomial problems
The WHONET software is well suited to analyze antibio-
grams in order to detect suspicious nosocomial outbreaks.
These functions too are dependant on the use of a consist-
ent battery of test drugs, and also works better when
results are entered as actual values for MIC or zone diam-
eters, as opposed to the interpreted value ("S", "I" or "R").
In our hospital, comparison of resistance rates did not
show dramatic variation between isolates from inpatients
and outpatients. The exception was a trend for more fre-
quent gentamicin-resistance in inpatient isolates of Gram-
negative bacteria, particularly Klebsiella spp., which may
suggest possible nosocomial spread. The analysis of anti-
biograms did not produce convincing evidence of clonal
patterns spread of bacterial isolates, possibly partly due to
the variations in the battery of antibiotics tested. Molecu-
lar methods for the evaluation of the genetic relatedness
of bacteria were not available in this study.
Suitability for international comparison of resistance data
In 2002 a total of 880 laboratories in 76 countries across
the world used the software, including 41 laboratories in
4 African countries. The WHONET system has been
implemented at MNH since 1998. Unfortunately, there is
no international consensus on a recommended method
for antimicrobial susceptibility testing. Worldwide at least
twelve different in vitro methods are followed, and only in
Europe the number is at least ten [5]. Furthermore, there
are ongoing changes in the interpretive criteria for suscep-
tibility testing [10]. In addition to this, there is an abun-
dance of molecular methods to describe various genetic
markers of resistance. In vivo clinical assessment is of great
importance in understanding bacterial drug resistance
and the gold standard for evaluating resistance in malaria
parasite. The multitude of methods employed for antimi-
crobial susceptibility testing has to some extent hampered
the meaningful sharing and comparison of resistance data
among countries. Recently, much work has been done in
Europe to harmonize resistance surveillance efforts across
country borders [33,34]. While many laboratories record
inhibition zones for disk diffusion results, interpretation
is usually according to national guidelines. Thus, suscep-
tibility patterns from different countries must be com-
pared prudently. The lack of standardization in methods
is a problem that must be addressed at an international
level.
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The surveillance system as a quality assurance tool
The implementation of the surveillance system brought
focus on methodological issues, including microbial
identification and susceptibility. The WHONET software
has built-in functions to alert the operator if isolates with
unexpected resistance patterns are entered. During the
surveillance exercise in our laboratory, it was discovered
that four isolates of Streptococcus pyogenes were reported as
resistant to penicillin. This was subsequently double-
checked, and consulting the laboratory bench-book we
found that clerical errors were the explanation for this.
The use of the surveillance software enabled the easy
detection, investigation and correction of such errors, and
consequently may contribute to increase the attention to
quality issues and generally improve the performance of
the lab. The current surveillance project highlighted some
methodological issues, most of which were caused by
budgetary limitations, such as the occasional use of
locally made antibiotic disks and limitations in the iden-
tification of organisms due to lack of reagents.
Impetus for further research
Routine surveillance makes use of available large data sets
at little additional cost and may be representative for a
greater part of the population. However, often it is neces-
sary to supplement the routine surveillance with ad hoc
studies aimed at investigating particular problems. While
ad hoc studies generally are more expensive to conduct,
they allow for the use of more advanced and expensive
laboratory methods and are better at targeting particular
populations of interest. The current surveillance study
identified a need for more data from bloodstream infec-
tions in order to provide reliable guidance for the treat-
ment of serious bacterial infections. As a consequence of
this, we started a study of bloodstream infections with the
pediatric department at the hospital. Another laboratory-
based research was started to ascertain the finding that
methicillin-resistance in staphylococci is still relatively
infrequent at this hospital.
Influencing popular opinion on antimicrobial resistance 
issues
Resistance surveillance is a platform from which to pro-
mote focus on antimicrobial resistance issues, both within
the hospital and the medical community, but also among
the general population. In conjunction with the surveil-
lance exercise, we have highlighted issues regarding anti-
microbials and resistance in local newspaper letters [35],
and there is ongoing work to establish a chapter of APUA
(Alliance for the prudent use of antibiotics, http://
www.apua.org) in Tanzania.
Cost considerations and human resources
The study suggests that laboratories, which perform sus-
ceptibility testing, can gain useful information on antimi-
crobial susceptibility with a minimal budget. As
appropriate software can be obtained free-of-charge, the
main cost of the surveillance system is associated with
purchasing a computer. However, there are other, indirect
costs, which may be attributed to the surveillance
program depending on the situation of the laboratory,
such as running costs for microbiologic procedures,
including susceptibility testing. Particularly, it is impor-
tant to ensure availability of antimicrobial discs of satis-
factory quality. A susceptibility surveillance system also
implies the need for some additional human resources for
data entry and analysis. In our experience, it is recom-
mendable to allocate approximately 50% of a laboratory
technologist position to this task. While the WHONET
program is excellent for entry, analysis and reporting of
resistance data, the software is not intended to function as
a complete patient management system for the labora-
tory. Data can be transferred from other databases into
WHONET by the use of a complementary software called
BacLink (also free-of-charge). However, in laboratories
such as ours, where the management of patients' labora-
tory tests (i.e. receipt of specimens and laboratory forms,
inscription in registers, return of test results, etcetera) is
handled manually via register-books, the data must be
punched into WHONET by hand. Since the WHONET
database is not used directly for patient management, the
surveillance activity tends to become less integrated in the
clinical routine work than it should. Thus, although the
program performs its task very well, in a long-term per-
spective, a surveillance system that is integrated with a
patient management system might be more sustainable. It
is difficult to quantify the potential benefits of a well-func-
tioning surveillance system. However, we are fully con-
vinced that the modest costs of the surveillance program
are highly justified since the data generated may improve
empiric therapy, help contain or prevent the further emer-
gence of antimicrobial resistance, decrease the need for
expensive second-line antimicrobial drugs and, ulti-
mately, save lives and reduce suffering.
Conclusions
It is imperative to preserve the effectiveness of common
antibiotics by promoting rational use of antibiotics based
on sound knowledge of local resistance patterns. In a hos-
pital with bacteriology services, the implementation of a
computerized surveillance system is a low-cost tool to
make use of available resistance data. In our hospital, the
resistance surveillance system has generated information
on resistance patterns that is useful as guidance for
empiric therapy of infections. It can help alert clinicians of
trends of antimicrobial resistance, guide drug-policy deci-
sions and facilitate rational use of drugs to prevent the fur-
ther emergence of antimicrobial resistance. The
surveillance system has also served as a quality assurance
tool and led to increased focus on antimicrobial resistance
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and prudent use of drugs. There is need for more data
from blood cultures for reliable guidance for the treat-
ment of severe, systemic bacterial infections. For antibi-
otic policy recommendations to be applicable for the
general population, more information is needed from
outpatients and rural areas.
There is limited information on antimicrobial resistance
trends on the African continent. Only four African coun-
tries use the WHONET system for antimicrobial resistance
surveillance, although some countries may use other sim-
ilar software. Recently much work has been done to estab-
lish consensus and a more standardized approach to
resistance surveillance in Europe [34]. Susceptibility data
based on recorded zone diameters, instead of interpreted
values ("S", "I" and "R"), would make the surveillance sys-
tem more effective in detecting subtle changes in antimi-
crobial resistance. We believe there is a need for a
standardized approach to antimicrobial resistance surveil-
lance also in the African region, as well as globally. This
would facilitate liaisons and sharing of information
among countries.
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